Status:

COMPLETED

Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

Lead Sponsor:

University of Chicago

Conditions:

Advanced Hematologic Malignancies

Leukemia

Eligibility:

All Genders

18-75 years

Phase:

PHASE1

PHASE2

Brief Summary

This is a clinical research study designed to evaluate whether a conditioning regimen consisting of the combination of three drugs named melphalan, alemtuzumab and clofarabine supported by donor blood...

Eligibility Criteria

Inclusion

  • Relapsed or refractory acute myelogenous or lymphoid leukemia
  • Chronic myelogenous leukemia in accelerated phase or blast-crisis
  • Chronic myelogenous leukemia in second or subsequent chronic phase
  • Recurrent or refractory malignant lymphoma or Hodgkin's disease
  • Multiple myeloma at high risk for disease recurrence
  • Chronic lymphocytic leukemia, relapsed or with poor prognostic features
  • Other Myeloproliferative disorder (polycythemia vera, essential thrombocythemia, myelofibrosis) with poor prognostic features
  • Myelodysplastic syndromes (including PNH) with \> 5% blasts
  • Zubroid performance status \< 2 (See Appendix B)
  • Life expectancy is not severely limited by concomitant illness
  • Adequate cardiac and pulmonary function. Patients with decreased LVEF or PFTS will be evaluated by cardiology or pulmonary prior to enrollment on this protocol
  • Calculated Creatinine Clearance \> 50 ml/min
  • Serum bilirubin 2.0 mg/dl, SGPT \< 3x upper limit of normal
  • No evidence of chronic active hepatitis or cirrhosis
  • HIV-negative
  • Patient is not pregnant
  • Patient or guardian able to sign informed consent

Exclusion

  • Clinical progression

Key Trial Info

Start Date :

March 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2013

Estimated Enrollment :

82 Patients enrolled

Trial Details

Trial ID

NCT00943592

Start Date

March 1 2006

End Date

November 1 2013

Last Update

February 27 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The University of Chicago

Chicago, Illinois, United States, 60637

Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies | DecenTrialz